On August 24-25, 2024, the "7th Advanced Training Course for Non Clinical Safety Evaluation of Drugs" was successfully held and concluded at the Huanghai Hotel in Qingdao City, Shandong Province, hosted by the Drug Safety Evaluation Research Professional Committee of the Chinese Pharmaceutical Association and jointly organized by Shandong Xinbo Pharmaceutical Research Co., Ltd. and Ocean University of China.

This training course attracted experts, scholars, and practitioners in the field of drug safety evaluation from all over the country to participate, jointly exploring and exchanging new theories, technologies, and methods of drug safety evaluation.

The theme of the training course is "Non clinical Safety Evaluation of Drugs under New Products, New Technologies, and New Situations", covering various aspects such as general knowledge, regulations and guidelines, and non clinical research of drugs. Authoritative experts and senior project leaders in the field of non clinical safety evaluation of domestic drugs were specially invited to provide in-depth explanations and discussions through various forms such as case analysis, trial design, evaluation strategies, and result analysis.

Shandong Xinbo Pharmaceutical Research Co., Ltd., as one of the organizers, not only provided high-quality conference services for this training course, but also the director of its safety evaluation center, Shen Lianzhong, and the general manager, Liu Baofeng, gave academic presentations during the training course, showcasing the company's professional strength and research achievements in the field of drug safety evaluation.

The successful holding of this training course not only enhances the professional technical level of the responsible persons in the field of drug safety evaluation, but also promotes communication and cooperation within the industry, which is of great significance for promoting the development of China's drug safety evaluation industry. Shandong Xinbo Pharmaceutical Research Co., Ltd. will continue to be committed to providing high-quality preclinical safety evaluation services for drugs, making greater contributions to the healthy development of China's pharmaceutical industry.